# China Pharma Holdings, Inc.: Form 10-Q for the period ended Jun 30, 2014

- Company: [China Pharma Holdings, Inc.](/companies/cphi.md) (CIK 1106644)
- Form: 10-Q
- Filed: 2014-08-14
- Accepted by EDGAR: Aug 14, 2014, 16:05 ET
- Period: 2014-06-30
- Accession: 0001010549-14-000422
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1106644/000101054914000422/cphi10q063014.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1106644/000101054914000422/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2014-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2014-04-01 to 2014-06-30 | $6.1m | us-gaap:Revenues |
| Revenue | 6 months, 2014-01-01 to 2014-06-30 | $13.2m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2014-04-01 to 2014-06-30 | $3.7m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2014-01-01 to 2014-06-30 | $8.2m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2014-04-01 to 2014-06-30 | $2.4m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2014-01-01 to 2014-06-30 | $5.1m | us-gaap:GrossProfit |
| Operating income | 3 months, 2014-04-01 to 2014-06-30 | −$8.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2014-01-01 to 2014-06-30 | −$10.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2014-04-01 to 2014-06-30 | −$113.4k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2014-01-01 to 2014-06-30 | −$169.8k | us-gaap:InterestExpense |
| Income tax | 3 months, 2014-04-01 to 2014-06-30 | $19.2k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2014-01-01 to 2014-06-30 | $38.5k | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 3 months, 2014-04-01 to 2014-06-30 | −$0.20 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2014-01-01 to 2014-06-30 | −$0.25 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2014-04-01 to 2014-06-30 | −$0.20 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2014-01-01 to 2014-06-30 | −$0.25 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months, 2014-01-01 to 2014-06-30 | $2.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2014-06-30 | $4.4m | us-gaap:Cash |
| Current assets | at 2014-06-30 | $69.0m | us-gaap:AssetsCurrent |
| Total assets | at 2014-06-30 | $146.0m | us-gaap:Assets |
| Current liabilities | at 2014-06-30 | $11.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2014-06-30 | $25.1m | us-gaap:Liabilities |
| Shareholders' equity | at 2014-06-30 | $120.9m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 31,133 characters.

The statements contained in this report with respect to our financial condition, results of operations and business that are not historical facts are forward-looking statements. Forward-looking statements can be identified by the use of forward-looking terminology, such as "anticipate", "believe", "expect", "plan", "intend", "seek", "estimate", "project", "could", "may" or the negative thereof or other variations thereon, or by discussions of strategy that involve risks and uncertainties. Management wishes to caution the readers of the forward-looking statements that any such statements that are contained in this report reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties and other factors, including, but not limited to, economic, competitive, regulatory, technological, key employees, and general business factors affecting our operations, markets, growth, services, products, licenses and other factors, some of which are described in this report and some of which are discussed in our other periodic filings with the Securities and Exchange Commission. These forward-looking statements are only estimates or predictions. No assurances can be given regarding the achievement of future results, as actual results may differ materially as a result of risks facing our company, and actual events may differ from the assumptions underlying the statements that have been made regarding anticipated events.

These risk factors should be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue. All written and oral forward looking statements made in connection with this report that are attributable to our company or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given these uncertainties, we caution investors not to unduly rely on our forward-looking statements. We do not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

### Business Overview & Recent Developments

The Chinese Food and Drug Administration (“CFDA”) promulgated *Good Manufacturing Practices for Pharmaceutical Products* (2010 revised version) (the “new GMP”) on February 12, 2011, which became effective on March 1, 2011. The new GMP outlines the basic principles and standards for the manufacturing of pharmaceutical products and the management of quality controls in the manufacturing process in the PRC. Pursuant to those mandatory requirements, the upgrading of our two sterilization production lines - liquid injectable and dry powder injectable product lines were required to be completed by the end of 2013. As of January 1, 2014, we had suspended such two production lines due to the failure to meet the GMP upgrading deadline. However, construction of the new main building has been completed, and two new sterilization production lines have been installed, and are in testing and commissioning. We have submitted the application for new GMP certificate at the end of June 2014. We believe that the GMP upgrading will be accomplished in good quality and expect the new GMP certificate to be issued in approximately three to six months from our submission of the application.

Once our new facility receives new GMP certificate and initiates production, we will begin upgrading our current existing old sterilization facility to meet new GMP standards and therefore expand our capacity in this product category.

The national CFDA staff was originally scheduled for an on-site-review of our new facility and production lines in late July of 2014. The review is a mandatory and major step in order for the new facility and production lines to receive the new GMP certification. The purpose is to check the compliance status of the new facility and production lines. However, due to a once-in-forty-year 16 grade super typhoon Rammasun hitting Haikou on July 18, 2014, the on-site-review was postponed to mid-August. We have taken emergency measures to restore and recover post-typhoon to be ready for the upcoming CFDA’s on-site-review. This typhoon caused considerable damage to our manufacturing facilities and inventory. Part of the warehouse was flooded; some machinery and equipment were destroyed while the water and electricity supply was suspended for several days causing stoppage to our production activities.

The Company’s initial estimate for loss exceeds $3.25 million (RMB20 million). The Company is still in the process of assessing the damage caused by the typhoon and this estimate may be updated in the future. The Company expects minor insurance compensation as only the new plant building was insured and the damage to it was minor. The old plant has restored to the operational mode at the end of July.

The products in our pipeline have experienced delays. The CFDA has increased the approval criteria and lengthened the process which requires additional supplemental materials and trials, higher cost, and longer approval time for all our products. Started from 2013, we commenced leading formulation screening, new technology exploration and technical criteria improvement activities. We expect this new model will improve our exploration channels for the pipeline products.

The status of our pipeline products remains the same as we reported in our Annual Report on Form 10-K for the year ended December 31, 2013.

In the three months ended June 30, 2014, we continued to execute our prudent marketing strategy to implement a more stringent screening on existing and potential distributors and hospital customers in terms of the speed of payment in order to gradually improve our trade turnover, especially in terms of the collection of our accounts receivable. This strategy temporarily impacts our sales in the current period by limiting our credit sales.

### Market Trends

Chinese pharmaceutical market is showing features of rapid expansion, fierce competition, low concentration, and is greatly influenced by government policies. According to Biao Dian Medical Information Co., Ltd. under the CFDA Southern Institute of Economic Research, the annual growth rate of Chinese healthcare market went beyond 20% during 2009-2011 due to the advancement of Healthcare Reform; however, this rate dropped below 20% in 2012 due to the limiting use of antibiotics and strengthening drug-price-control policies issued that year; and this rate further dropped to 15.64% in 2013 due to the impact of continuous drug-price-control policy, anti-commercial bribery, and the new GMP requirement.

A series of changes in the market position of the different categories of medication occurred along with the changes in disease spectrum and prescription habits: the decrease in the systemic use of anti-infection drugs in hospitals became the most significant trend. The market share of anti-infection drugs decreased to 15.3% in 2013, which represented a decrease of roughly 9% from 24.5% in 2007 per “*China Pharmaceutical Market Development Blue Book (2014)" (*the “*Blue Book”)*, which was mainly due to a better understanding of antibiotic abuse problems, policy instruction of price cutting in antibiotics, and the release of “*Clinical Use of Antibiotics Hierarchical Management Approach”*. Meanwhile, the market shares of central nerve system category (CNS) and digestive category increased slightly to 14.5% and 14.1% in 2013 from 13.3% and 12.5% in 2007 per the “*Blue Book”*. It is notable that Traditional Chinese Medicine (TCM) had better performance compared to chemical medicines in the above two categories, which decelerate the sale increase for the latter. All the changes mentioned above had impacted most of our existing products.

In July 2014, National Health Commission of PRC rearranged “New Rural Cooperative Medical System” (NRCMS) for the year 2014, which stated the key projects this year as follows: improving funding level, promoting insurance for major diseases, adjusting payment policy, and strengthening fund supervision. It clearly stipulated that the NRCMS fund surplus accumulated this year cannot exceed 25% of the total financing. We believe that at least more than RMB13 billion of new funds will be spent in order to achieve this standard, which could effectively mitigate the adversity of "healthcare payment control". This change in industrial environment might bring positive impacts to the collection of our accounts receivables because our government-backed hospital clients could potentially be benefited from such funding from the government.

### Results of Operations for the Three Months Ended June 30, 2014

### Revenue

Revenue for the three months ended June 30, 2014 was $6.1 million, decreased by 24% from $8.0 million for the three months ended June 30, 2013. This was mainly due to the production suspension of our injectable production lines this year.

We suspended production of our dry powder injectable and liquid injectable products at our two old production lines as of January 1, 2014 due to the failure to meet the GMP upgrading deadline. Expecting that this shutdown would affect our sales in 2014, we had gradually increased inventory levels of certain products in advance in order to support the market demand for these products. We planned to upgrade these two production lines once our GMP facility starts operation.

Set forth below are our revenues by product categories in millions USD for the three months ended June 30, 2014 and 2013:

| Product Category 2014 | Three Months Ended June 30, 2013 |  | Net Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Anti-Viro/ Infection & Respiratory | $4.18 | $4.09 | $0.09 | 2% |
| CNS Cerebral & Cardio Vascular | $0.99 | $1.98 | -$0.99 | -50% |
| Digestive Diseases | $0.45 | $0.97 | -$0.51 | -53% |
| Other | $0.50 | $0.97 | -$0.46 | -48% |

“Anti-Viro/ Infection &Respiratory” category increased by $0.09 million to $4.18 million in the second quarter in 2014 compared to $4.09 million in the same period in 2013, which was mainly due to the sales increase in Cefaclor.

The most significant decrease in revenue was in our “CNS Cerebral & Cardio Vascular” product category, which generated $0.99 million in sales revenue in the second quarter of 2014 compared to $1.98million in the same period a year ago, decreased by $0.99 million. This decrease was mainly due to having injectables as the main product in this category. The suspension of injectables production line since the beginning of this year has negatively impacted the sales performance.

Sales of the “Digestive Diseases” decreased by $0.51 million to $0.45 million in the second quarter in 2014 compared to $0.97 million in the same period in 2013, mainly due to the decrease in sales of Compound Ammonium Glycyrrhetate S and Tiopronin, which were affected primarily by market volatility.

Our “Other” category generated $0.5 million of sales in the second quarter in 2014, compared to $0.97 million in the same period last year, or a decrease of $0.46 million. This decrease was mainly due to the decrease in sales of an injectable product Vitamin B6 in this category.

In the three months ended June 30, 2014, revenue breakdown by product category showed some changes. Sales of the “Anti-Viro / Infection & Respiratory” products category represented 68% of total sales in the three months ended June 30, 2014, compared to 51% in the same period last year. The “CNS, Cerebral & Cardio Vascular” category represented 16% of total revenue in the three months ended June 30, 2014 and 25% in the same period last year. The “Digestive Diseases” category represented 7% of total revenue in three months ended June 30, 2014, remaining comparably flat as in the same period last year. The “Other” category represented 9% and 17% of revenues in three months ended June 30, 2014 and 2013, respectively.

### Cost of Revenue

For the three months ended June 30, 2014, our cost of revenue was $3.7 million, or 61% of total revenue, which represented a decrease of $2.1 million from $5.8 million, or 73% of total revenue, in the second quarter of 2013. The decrease in cost of revenue in the second quarter of 2014 was mainly due to the decrease in purchasing prices of certain raw materials due to market fluctuations.

### Gross Profit (Loss) and Gross Margin

Gross profit for the three months ended June 30, 2014 was $2.4 million, an increase of $0.3 million, from gross profit of $2.2 million in the same period of 2013. Our gross profit margin in the second quarter of 2014 was 39% compared to 27% in the same period of 2013. The increase in gross profit margin was mainly due to the decrease in purchasing prices of certain raw materials and the increase in selling prices of certain products due to market fluctuation during this period. Looking forward, we expect pricing pressures on most products, while our new products would support overall gross margin once they are launched. We launched Candesartan in November, 2013 and started recognizing its sales revenue in this quarter.

### Selling Expenses

Our selling expenses for the three months ended June 30, 2014 were $0.6 million, compared to $0.7 million in the same period last year. Selling expenses accounted for 10% of the total revenue in the second quarter 2014 compared to 9% in the same period in 2013. Due to many adjustments in our selling processes under healthcare reform policies, despite the decrease in sales, we still require comparable personnel and expenses to support our revenue and collection of accounts receivable.

### General and Administrative Expenses

Our general and administrative expenses for the three months ended June 30, 2014 were $0.4 million, a decrease of $0.2 million from $0.6 million in the same period 2013. General and administrative expenses accounted for 6% and 7% of our total revenues in the three months ended June 30, 2014 and 2013, respectively.

### Research and Development Expenses

Our research and development expenses for the three months ended June 30, 2014 and 2013 were $1.9 million and $0.9 million, respectively. The change in research and development expense was mainly due to the costs related to testing of the new production lines and the payment schedule per milestone stated in the contracts.

### Bad Debt Expenses

Our bad debt expenses for the three months ended June 30, 2014 and 2013 were $8.0 million and $4.8 million, respectively. The increase in bad debt expenses was mainly due to the increase in the aged accounts receivable.

In general, our normal credit or payment terms extended to customers are 90 days. This has not changed in recent years. Due to the peculiarity of the Chinese pharmaceutical market environment, deferred payments to pharmaceutical companies by state-owned hospitals and local medicine distributors are a normal phenomenon. Our customers are primarily pharmaceutical distributors who sell products to mostly government-backed hospitals. Therefore, the age of our receivables from our customers tends to be long. Although these customers typically pay after the due date of the receivables, since the majority of hospitals in China are backed by the government, management believes that the deferred payments from state-owned hospitals are secured and will eventually be collected.

The amount of accounts receivable that were past due (or the amount of accounts receivable that were more than 90 days old) was $33.9 million and $40.1 million as of June 30, 2014 and December 31, 2013, respectively. The following table illustrates our accounts receivable aging distribution in terms of percentage of total accounts receivable as of June 30, 2014 and December 31, 2013.

|  | June 30, 2014 | December 31, 2013 |
| --- | ---: | ---: |
| 1 - 90 Days | 5.6% | 8.0% |
| 90 - 180 Days | 5.5% | 7.4% |
| 180 - 360 Days | 11.0% | 23.3% |
| 360 - 720 Days | 42.3% | 61.3% |
| \> 720 Days | 35.6% | 0.0% |
| Total | 100.0% | 100.0% |

Our bad debt allowance estimate is currently the sum of 3.5% of accounts receivable that are less than 365 days old, 10% of accounts receivable that are between 365 days and 720 days old and 100% of accounts receivable that are greater than 720 days old.

In order to collect cash to support the construction of our new plant to meet the policy requirements for new GMP upgrading, we have shifted to prudent sales strategies in the recent two years. This strategy strengthened the preference on sales of customers with good credit performance, while reduced the supplement to customers with poor credit record. On one hand, this strategy contributed to the recovery of funds; on the other hand, it negatively impacted our sales and indirectly prolonged the payment from the estranged customers. These two factors resulted in increased proportion of our older-aged accounts receivable balance.

The management has paid high attention to this issue: it evaluated the collection conditions of the relevant departments, and further considered taking a series of targeted measures to promote collection of older-aged accounts receivable in the next quarter.

### Loss from Operations

Our operating loss for the three months ended June 30, 2014 was $8.5 million, compared to operating loss of $4.8 million in the same period in 2013. The increase in operating loss was primarily due to the decrease in sales and the increase in bad debt expense and R&D expense recognized by the three months ended June 30, 2014.

### Income Tax Expense (Benefit)

For the three months ended June 30, 2014 and 2013, our income tax rate was 15%. Income tax expense was $0.02 million for the three months ended June 30, 2014, and income tax benefit was $0.4 million for the three months ended June 30, 2013. The income taxes recognized for the three months ended June 30, 2014 and 2013 were related to net changes in long-term deferred tax assets and liabilities. We renewed our "National High-Tech Enterprise" status ("National HT Status") from the PRC government in the third quarter of 2013. With this designation, for the years ended December 31, 2014, 2015 and 2016, we will continue to enjoy a preferential tax rate of 15% which is notably lower than the statutory income tax rate of 25%.

### Net Loss

Net loss for three months ended June 30, 2014 and 2013 were $8.6 million and $4.5 million, respectively. The increase in net loss was primarily due to the decrease in sales, the increase in bad debt expense and R&D expense recognized for the three months ended June 30, 2014.

For the three months ended June 30, 2014, loss per basic and diluted common share was $0.20, compared to loss per basic and diluted share of $0.10 for the same period in 2013.

The number of basic and diluted weighted-average outstanding shares used to calculate loss per share was 43,579,557 for the three months ended June 30, 2014 and 2013, respectively.

### Six Months Ended June 30, 2014 and 2013

### Revenue

For the six months ended June 30, 2014, our sales revenue decreased by $3.0 million, or 19%, to $13.2 million from the $16.8 million in the corresponding period of 2013.

Set forth below are our revenues by product categories in millions USD for each of the six months ended June 30, 2014 and 2013.

### Sales Revenue by Major Category (Dollars in Millions)

| Product Category 2014 | Six Months Ended June 30, 2013 |  | Net Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Anti-Viro/ Infection & Respiratory | $9.15 | $8.73 | $0.42 | 5% |
| CNS Cerebral & Cardio Vascular | $1.90 | $4.10 | -$2.20 | -54% |
| Digestive Diseases | $0.77 | $1.79 | -$1.02 | -57% |
| Other | $1.41 | $1.63 | -$0.22 | -13% |

During the first half of fiscal 2014, our overall sales revenue decreased by 19% on a year-over-year basis led by the CNS Cerebral & Cardio Vascular and Digestive categories. Sales in the Anti-Viro/ Infection & Respiratory category reached $9.2 million, an increase of $0.4 million, or 5%, compared to $8.7 million in the same period last year, which was mainly due to the sales increase in Cefaclor. CNS Cerebral & Cardio Vascular category decreased by $2.2 million, or 54%, to $1.9 million from $4.1 million due to the suspension of injectable production lines. Sales in Digestive category decreased by $1.0 million, or 57%, to $0.8 million from $1.8 million, which was mainly due to the sales decrease of injectable products in this category. Sales of the “Other” category decreased by $0.2 million, or 13%, to $1.4 million from $1.6 million.

### Gross Margin and Gross Profit

Gross profit for the six months ended June 30, 2014 was $5.0 million, compared to $0.6 million in the same period 2013. Gross profit margin for the six months ended June 30, 2014 and 2013 were 38% and 4% respectively. Without the effect of inventory obsolescence in the first half of 2013, management estimates that our gross profit would have been approximately $4.3 million, and gross margin would have been 26%. The increase in gross profit margin was mainly due to market fluctuation and sales price increases in certain products; in addition, more high-margin products were sold in the first half of 2014 compared to the same period a year ago.

### Selling Expenses

Our selling expenses for the six months ended June 30, 2014 were $1.4 million, a decrease of 4%, compared to $1.5 million for the six months ended June 30, 2013. Selling expenses were approximately 11% of revenue in the first half of 2014 compared to 9% during the comparable period a year ago.

### General Administrative Expenses

Our general and administrative expenses for the six months ended June 30, 2014 were $0.8 million, a decrease of $0.4 million, or 31%, compared to $1.2 million for the same period in 2013. This decrease was mainly due a financial consulting fee incurred in the first half of 2013 for the preparation of the construction loan facility.

### Research and Development Expenses

Our research and development expenses for the six months ended June 30, 2014 and 2013 were $2.3 million and $1.0 million, respectively. The change in research and development expenses was mainly due to the costs related to testing of the new production lines and the payment schedule per milestone stated in contracts.

### Bad Debt Expenses

Our bad debt expenses for the six months ended June 30, 2014 was $11.3 million, compared to $4.6 million for the same period in 2013. Please see additional discussion of bad debt and account receivables in the section above named "Bad Debt Expense".

We recognize bad debt expense per actual write-offs as well as the changes of allowance for doubtful accounts. To the extent that our current allowance for doubtful accounts is higher than that of the previous period, we recognize a bad debt expense for the difference between the two periods; when the current allowance is lower than that of the previous period, we recognize a bad debt benefit for the difference. The allowance for doubtful accounts was $24.5 million and $13.3 million as of June 30, 2014 and December 31, 2013, respectively. Therefore, the changes in the allowance for doubtful accounts during the six months ended June 30, 2014 and 2013 were as follows:

|  | For the Six Months Ended June 30, 2014 | 2013 |
| --- | ---: | ---: |
| Balance, Beginning of Period | $13,301,622 | $4,429,945 |
| Bad debt expense (benefit) | 11,340,444 | 4,752,733 |
| Foreign currency translation adjustment | -142,705 | 14,315 |
| Balance, End of Period | $24,499,361 | $9,196,993 |

### Loss from Operations

Our operating loss for the six months ended June 30, 2014 was approximately $10.9 million, compared to $7.8 million for the same period in 2013, which represented a deterioration of $3.1million. The deterioration in operating income performance was primarily due to lower revenue, higher bad debt and R&D expense in the current period compared to the corresponding period one year ago.

### Net Loss

Our net loss for the six months ended June 30, 2014 and 2013 was $11.0 million and $7.3 million, respectively. The deterioration in net income performance was primarily due to lower revenue, higher bad debt expense and R&D expense in the current period compared to the corresponding period one year ago.

### Liquidity and Capital Resources

Our principal sources of liquidity are cash generated from operations and short-term bank loans. Our cash and cash equivalents were $4.4 million, which represents 3% of our total assets as of June 30, 2014, as compared to $6.0million, which represents 4% of our total assets as of December 31, 2013. All of the $4.4 million of cash and cash equivalents at June 30, 2014 is considered to be reinvested indefinitely in Helpson and is not expected to be available for payment of dividends, for other payments to our parent company or to its shareholders. As of June 30, 2014, we had a principal balance of $4.9 million in short-term bank loans. In addition, we entered into an eight-year construction loan facility with a bank on June 21, 2013. The total loan facility amount is RMB 80,000,000 (approximately $13 million), which had been fully utilized through May 7, 2014. The cash flow generated from operating activities was used to fund the remaining construction of our GMP upgrading project.

Based on our current operating plan, management believes that our cash provided by operations will be sufficient to meet our operation capital needs and our anticipated capital expenditures, including expenditures for new formula acquisitions and GMP upgrading related construction and equipment, for the next twelve months. However, if events or circumstances change and we do not meet our operating plan as expected, we may be required to seek additional capital and/or to reduce certain discretionary spending, which could have a material adverse effect on our ability to achieve our business objectives. Notwithstanding the foregoing, when we regard market conditions are most advantageous, we may seek additional financing as necessary for expansion purposes, which may include debt and/or equity financing. There can be no assurance that any additional financing will be available on acceptable terms, if at all.

### Operating Activities

Net cash provided by operating activities was $2.4 million in the six months ended June 30, 2014 compared to $3.1 million for the same period in 2013.

At June 30, 2014, our accounts receivable was $35.9 million, a decrease of $9.2 million from $45.1 million at December 31, 2013. The decrease was due to our enhanced collection efforts as well as the increased allowance for doubtful accounts at June 30, 2014 compared to December 31, 2013.

At June 30, 2014, total inventory was $21.0million, a decrease of $3.7 million from $24.7 million at December 31, 2013. This decrease was mainly due to decreased purchases of raw materials for injectable products and additional inventory needs from R&D expense for trial productions at the new facility.

### Investing Activities

During the six months ended June 30, 2014, net cash used in investing activities was $4.6 million, stayed flat to the same period in 2013. The investment spending in the first half of 2014 was mainly for the GMP upgrading related construction and equipment.

### Financing Activities

There was $0.6 million cash flow provided from financing activities in the six months ended June 30, 2014 and there were no financing activities for the same period in 2013. The financing activities that occurred in the first half of 2014 were related to the construction loan facility described under the first paragraph in this section entitled “Liquidity and Capital Resources”.

According to relevant PRC laws, companies registered in the PRC, including our PRC subsidiary, Helpson, are required to allocate at least ten percent (10%) of their after-tax net income, as determined under accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account balances reach fifty percent (50%) of the companies’ registered capital prior to their remittance of funds out of the PRC. Allocations to these reserves and funds can only be used for specific purposes and are not transferrable to the parent company in the form of loans, advances or cash dividends. As of June 30, 2014 and December 31, 2013, the net assets of Helpson were $115,810,000 and $127,626,000, respectively. Due to the restriction on dividend distribution to overseas shareholders, the amount of Helpson’s net assets designated for general and statutory capital reserves, and thus could not be transferred to our parent company as cash dividends, were $8,182,770 and $8,182,770 (50% of registered capital) at June 30, 2014 and December 31, 2013, respectively. Since the amount that Helpson must set aside for the statutory surplus fund only accounts for 7.1% and 6.4%, respectively, of its total net assets, this reserve does not have a major impact on our liquidity. There were no allocations to the statutory surplus reserve accounts during the six months ended June 30, 2014.

The PRC government also imposes controls on the conversion of RMB into foreign currencies and the remittance of currencies out of the PRC. Our businesses and assets are primarily denominated in RMB. All foreign exchange transactions take place either through the People’s Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the People’s Bank of China. Approval of foreign currency payments by the People’s Bank of China or other regulatory institutions requires submitting a payment application form together with applicable invoices and signed contracts. These currency exchange control procedures imposed by the PRC government authorities may restrict the ability of Helpson, our PRC subsidiary, to transfer its net assets to our parent company through loans, advances or cash dividends.

### Off Balance Sheet Arrangements

As of June 30, 2014, we did not have any off-balance sheet arrangements.

### Commitments

At June 30, 2014, we were obligated to pay laboratories and others approximately $5.42 million over approximately the next four years upon completion of the various phases of contracts to provide CFDA production approval of medical formulas.

### Critical Accounting Policies

Management's discussion and analysis of its financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. Our financial statements reflect the selection and application of accounting policies which require management to make significant estimates and judgments. The discussion of our critical accounting policies contained in Note 1 to our consolidated financial statements, “Organization and Significant Accounting Policies”, is incorporated herein by reference.

## Market risk

As filed, 139 characters.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this item.

## Controls and procedures

As filed, 1,951 characters.

### Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and interim Chief Financial Officer, evaluated the effectiveness of our “disclosure controls and procedures” (as defined in the Securities Exchange Act of 1934 (the “Exchange Act”) Rules 13a-15(e) or 15d-15(e)) as of the end of the period covered by this quarterly report. Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act (a) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (b) is accumulated and communicated to management, including our Chief Executive Officer and interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives as described above. Based on this evaluation, our Chief Executive Officer and interim Chief Financial Officer concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective.

### Changes in Internal Controls over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed Aug 14, 2014.
Source: SEC EDGAR, the filing index for accession 0001010549-14-000422. Last ingested by Listed: Nov 11, 2026, 00:23 ET. No prices; not investment advice.
